Weight loss in patients with type 2 diabetes receiving once‐weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post‐hoc analysis of the AWARD‐4 study across baseline body mass index subgroups

2019 ◽  
Vol 21 (6) ◽  
pp. 1340-1348 ◽  
Author(s):  
Martin Fuechtenbusch ◽  
Jens Aberle ◽  
Elke Heitmann ◽  
Claudia Nicolay ◽  
Heike Jung
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Weight Loss ◽  
Insulin Glargine ◽  
Body Mass ◽  
Insulin Lispro ◽  
Baseline Body Mass Index ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial

2021 ◽  
Author(s):  
Megan O. Bensignor ◽  
Eric M. Bomberg ◽  
Carolyn T. Bramante ◽  
T. V. S. Divyalasya ◽  
Paula M. Hale ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Children And Adolescents ◽  
Body Mass ◽  
Post Hoc Analysis ◽  
Post Hoc

651-P: Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 651-P
Author(s):  
ENZO BONORA ◽  
JUAN P. FRIAS ◽  
RALEIGH MALIK ◽  
ANITA KWAN ◽  
SOHINI RAHA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Post Hoc Analysis ◽  
Induce Weight Loss ◽  
Post Hoc ◽  
Baseline Bmi ◽  
Higher Doses

scholarly journals Frequency of Genital Infections According to Body Mass Index in Dapagliflozin-treated Patients with Type 2 Diabetes Mellitus

2017 ◽  
Vol 04 (01) ◽  
pp. e1-e4
Author(s):  
Gottfried Rudofsky ◽  
Tanja Haenni ◽  
John Xu ◽  
Eva Johnsson
Keyword(s):  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Body Mass ◽  
The Body ◽  
Baseline Body Mass Index ◽  
Obese Patients ◽  
Genital Infections ◽  
Increased Risk ◽  
Three Body

Abstract Genital infections are associated with sodium glucose co-transporter 2 inhibitors such as dapagliflozin. Since patients with Type 2 diabetes are at increased risk of genital infections, and obesity is a risk factor for infections, obese patients with Type 2 diabetes could be more susceptible to genital infections when treated with sodium glucose co-transporter 2 inhibitors. This pooled dataset assessed the frequency of genital infections according to baseline body mass index in patients treated with dapagliflozin 10 mg. Data were pooled from 13 studies of up to 24 weeks’ duration (dapagliflozin N=2 360; placebo N=2 295). Frequency of genital infections was compared between three body mass index subgroups (<30, ≥30−< 35 and ≥35 kg/m2). Genital infections were reported in 130 (5.5%) patients receiving dapagliflozin and 14 (0.6%) patients receiving placebo; none of which were serious. Genital infections were more common in women (84/130 [64.6%]) than in men (46/130 [35.4%]) treated with dapagliflozin. In the body mass index < 30, ≥ 30−< 35 and ≥ 35 kg/m2 dapagliflozin-treated subgroups, 38/882 (4.3%), 47/796 (5.9%) and 45/682 (6.6%) patients presented with genital infections, respectively. Although the frequency was low overall and relatively similar between subgroups, there was a trend towards an increase in genital infections in patients with a higher body mass index. This trend is unlikely to be clinically relevant or to affect suitability of dapagliflozin as a treatment option for obese patients with Type 2 diabetes, but rather should influence advice and counselling of overweight patients on prevention and treatment of genital infections.

Sign in / Sign up

Export Citation Format

Share Document